RESUMEN
Activated platelets and neutrophils exacerbate atherosclerosis. Platelets release the chemokines CXCL4, CXCL4L1 and CCL5, whereas myeloperoxidase (MPO) and azurocidin are neutrophil-derived. We investigated whether plasma levels of these platelet and neutrophil mediators are affected by the acute coronary syndrome (ACS), its medical treatment, concomitant clinical or laboratory parameters, and predictive for the progression of coronary artery disease (CAD). In an observational study, the association of various factors with plasma concentrations of platelet chemokines and neutrophil mediators in 204 patients, either upon admission with ACS and 6 hours later or without ACS or CAD, was determined by multiple linear regression. Mediator release was further analysed after activation of blood with ACS-associated triggers such as plaque material. CXCL4, CXCL4L1, CCL5, MPO and azurocidin levels were elevated in ACS. CXCL4 and CCL5 but not CXCL4L1 or MPO were associated with platelet counts and CRP. CXCL4 (in association with heparin treatment) and MPO declined over 6 hours during ACS. Elevated CCL5 was associated with a progression of CAD. Incubating blood with plaque material, PAR1 and PAR4 activation induced a marked release of CXCL4 and CCL5, whereas CXCL4L1 and MPO were hardly or not altered. Platelet chemokines and neutrophil products are concomitantly elevated in ACS and differentially modulated by heparin treatment. CCL5 levels during ACS predict a progression of preexisting CAD. Platelet-derived products appear to dominate the inflammatory response during ACS, adding to the emerging evidence that ACS per se may promote vascular inflammation.
Asunto(s)
Síndrome Coronario Agudo/diagnóstico , Plaquetas/metabolismo , Quimiocinas/sangre , Mediadores de Inflamación/sangre , Inflamación/diagnóstico , Síndrome Coronario Agudo/sangre , Síndrome Coronario Agudo/tratamiento farmacológico , Síndrome Coronario Agudo/genética , Síndrome Coronario Agudo/inmunología , Anciano , Anticoagulantes/uso terapéutico , Péptidos Catiónicos Antimicrobianos/sangre , Biomarcadores/sangre , Plaquetas/efectos de los fármacos , Plaquetas/inmunología , Proteínas Sanguíneas , Proteínas Portadoras/sangre , Estudios de Casos y Controles , Quimiocina CCL5/sangre , Quimiocina CCL5/genética , Quimiocinas/genética , Progresión de la Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Heparina/uso terapéutico , Humanos , Inflamación/sangre , Inflamación/inmunología , Modelos Lineales , Masculino , Persona de Mediana Edad , Neutrófilos/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/metabolismo , Peroxidasa/sangre , Recuento de Plaquetas , Polimorfismo de Nucleótido Simple , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Factores de TiempoAsunto(s)
Adenosina Difosfato/sangre , Eritrocitos/metabolismo , Agregación Plaquetaria , Pruebas de Función Plaquetaria , Trombosis/diagnóstico , Electrodos , Humanos , Pruebas de Función Plaquetaria/instrumentación , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Manejo de Especímenes , Trombosis/sangreRESUMEN
Lysophosphatidic acid (LPA), a component of mildly-oxidized LDL and the lipid rich core of atherosclerotic plaques, elicits platelet activation. LPA is the ligand of G protein-coupled receptors (GPCR) of the EDG family (LPA(1-3)) and the newly identified LPA(4-7) subcluster. LPA(4), LPA(5) and LPA(7) increase cellular cAMP levels that would induce platelet inhibition rather than activation. In the present study we quantified the mRNA levels of the LPA(1-7) GPCR in human platelets and found a rank order LPA(4) = LPA(5) > LPA(7) > LPA(6) = LPA(2) >> LPA(1) > LPA(3). We examined platelet shape change using a panel of LPA receptor subtype-selective agonists and antagonists and compared them with their pharmacological profiles obtained in heterologous LPA(1-5) receptor expression systems. Responses to different natural acyl and alkyl species of LPA, and octyl phosphatidic acid analogs, alpha-substituted phosphonate analogs, N-palmitoyl-tyrosine phosphoric acid, N-palmitoyl-serine phosphoric acid were tested. All of these compounds elicited platelet activation and also inhibited LPA-induced platelet shape change after pre-incubation, suggesting that receptor desensitization is likely responsible for the inhibition of this response. Fatty acid free albumin (10 microM) lacking platelet activity completely inhibited platelet shape change induced by LPA with an IC(50) of 1.1 microM but had no effect on the activation of LPA(1,2,3,&5) expressed in endogenously non-LPA-responsive RH7777 cells. However, albumin reduced LPA(4) activation and shifted the dose-response curve to the right. LPA(5) transiently expressed in RH7777 cells showed preference to alkyl-LPA over acyl-LPA that is similar to that in platelets. LPA did not increase cAMP levels in platelets. In conclusion, our results with the pharmacological compounds and albumin demonstrate that LPA does not induce platelet shape change simply through activation of LPA(1-5), and the receptor(s) mediating LPA-induced platelet activation remains elusive.
Asunto(s)
Plaquetas/efectos de los fármacos , Lisofosfolípidos/farmacología , Receptores del Ácido Lisofosfatídico/sangre , Albúmina Sérica Bovina/farmacología , Animales , Plaquetas/metabolismo , Plaquetas/ultraestructura , Células CHO , Forma de la Célula/efectos de los fármacos , Cricetinae , Cricetulus , AMP Cíclico/sangre , Femenino , Humanos , Lisofosfolípidos/antagonistas & inhibidores , Masculino , Modelos Químicos , Ácidos Fosfatidicos/farmacología , Activación Plaquetaria/efectos de los fármacos , Activación Plaquetaria/fisiología , ARN Mensajero/biosíntesis , ARN Mensajero/sangre , ARN Mensajero/genética , Ratas , Receptores del Ácido Lisofosfatídico/agonistas , Receptores del Ácido Lisofosfatídico/antagonistas & inhibidores , Receptores del Ácido Lisofosfatídico/biosíntesis , Albúmina Sérica Bovina/química , Relación Estructura-ActividadRESUMEN
Pathological blood platelet activation promotes thrombosis in cancer patients, but the specific substances involved are still under investigation. Tumor exudates have been described to contain lysophosphatidic acid (LPA), a known platelet-activating substance, and the concentration of mediators present in malignant ascites are constantly equilibrated with the concentration in plasma. We hypothesized that the ascites of cancer patients might activate platelets, and that this may be caused by LPA. Indeed, ascites samples from 15 different patients with cancer induced shape change and an increase of cytosolic Ca2+ of isolated platelets; both responses were cross-desensitized by lysophosphatidic acid (LPA), but not by other platelet stimuli. Moreover shape change, Ca2+ mobilization and aggregation induced by ascites could be completely blocked by pretreatment of platelets with specific LPA-receptor antagonists. Phospholipids were extracted from ascites, separated by thin layer chromatography, and individual fractions were tested for activity on platelets. The platelet activating substance co-migrated with LPA, whereas other fractions were inactive. Notably, ascites induced through LPA-receptor activation platelet aggregation in whole blood. Our results suggest that LPA plays an essential role in the pathological platelet activation in cancer patients. We propose that LPA receptor antagonists could be effective in blocking cancer-associated platelet activation and thus preventing thrombosis.
Asunto(s)
Ascitis/metabolismo , Ascitis/patología , Plaquetas/efectos de los fármacos , Lisofosfolípidos/farmacología , Activación Plaquetaria/efectos de los fármacos , Plaquetas/fisiología , Calcio/metabolismo , Señalización del Calcio/efectos de los fármacos , Neoplasias Hematológicas/química , Neoplasias Hematológicas/metabolismo , Neoplasias Hematológicas/patología , Humanos , Agregación Plaquetaria/efectos de los fármacos , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/metabolismo , Receptores del Ácido LisofosfatídicoAsunto(s)
Proteínas Inmediatas-Precoces/fisiología , Lisofosfolípidos , Músculo Liso Vascular/efectos de los fármacos , Receptores de Superficie Celular , Receptores Acoplados a Proteínas G , Esfingosina/farmacología , Animales , Animales Recién Nacidos , División Celular/efectos de los fármacos , Movimiento Celular/efectos de los fármacos , Células Cultivadas , Regulación de la Expresión Génica/efectos de los fármacos , Proteínas Inmediatas-Precoces/genética , Músculo Liso Vascular/citología , Músculo Liso Vascular/metabolismo , Isoformas de Proteínas/genética , ARN Mensajero/efectos de los fármacos , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Receptores Lisofosfolípidos , Esfingosina/análogos & derivadosRESUMEN
Platelet shape change was found to be associated with an increase in protein tyrosine phosphorylation upon stimulation of thrombin-, ADP- and thromboxane A2-G-protein coupled receptors in human platelets and thromboxane A2 receptors in mouse platelets. By using PP1 and PD173956, two structurally unrelated specific inhibitors of Src-family tyrosine kinases, and mouse platelets deficient in the Src-kinase Fyn or Lyn, we show that Src-family kinases cause the increase in protein tyrosine phosphorylation. We further detected that the non-Src tyrosine kinase Syk was activated during shape change in a manner dependent on Src-family kinaseactivation. The pharmacological experiments and the studies on Fyn-, Lyn- and Syk-deficient mouse platelets showed that neither Src-family kinases nor Syk are functionally involved in shape change. Also human platelets deficient of the tyrosine kinase Btk showed a normal shape change. Binding of PAC-1 that recognizes activated integrin alphaIIb beta3 complexes on the platelet surface was enhanced during shape change and blocked by inhibition of Src-kinases. We conclude that the activation of Src-kinases and the subsequent Syk stimulation upon activation of G-protein coupled receptors are not involved in the cytoskeletal changes underlying shape change of human and mouse platelets, but that the stimulation of this evolutionary conserved pathway leads to integrin alphaIIb beta3 exposure during shape change.
Asunto(s)
Proteínas Tirosina Quinasas/farmacología , Agammaglobulinemia Tirosina Quinasa , Animales , Plaquetas/citología , Plaquetas/enzimología , Tamaño de la Célula/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Precursores Enzimáticos/efectos de los fármacos , Precursores Enzimáticos/genética , Precursores Enzimáticos/farmacología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Ratones , Ratones Noqueados , Nefelometría y Turbidimetría , Fosforilación/efectos de los fármacos , Activación Plaquetaria/efectos de los fármacos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/efectos de los fármacos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Proteínas Tirosina Quinasas/deficiencia , Proteínas Tirosina Quinasas/efectos de los fármacos , Proteínas Tirosina Quinasas/genética , Proteínas Tirosina Quinasas/fisiología , Quinasa Syk , Familia-src Quinasas/antagonistas & inhibidores , Familia-src Quinasas/farmacologíaRESUMEN
Activation of the collagen receptor glycoprotein VI (GPVI) by a collagen-related peptide (CRP) induces stimulation of platelets and megakaryocytes through the phosphatidylinositol (PI) 3-kinase-dependent pathway leading to activation of Bruton tyrosine kinase (Btk) and phospholipase Cgamma2 (PLCgamma2). Here, we present evidence that both proteins undergo PI 3-kinase-dependent translocation to the plasma membrane on CRP stimulation that is markedly inhibited by wortmannin and LY294002. Translocation of PLCgamma2 but not Btk is also seen in megakaryocytes from X-linked immunodeficiency mice, which have a mutation that reduces the affinity of the pleckstrin homology (PH) domain of Btk for PI 3,4,5-trisphosphate (PI 3,4,5-P3). Activation of PC12 cells by epidermal growth factor (EGF) results in increased PI 3-kinase activity and high PI 3,4,5-P3 levels that trigger translocation of the green fluorescent protein (GFP)-labeled PH of Btk, but not the GFP-labeled PH and tandem Src homology 2 (SH2) domains of PLCgamma2. In contrast to the results with CRP, the G protein-coupled receptor agonist thrombin stimulates PI 3-kinase-independent translocation of Btk but not PLCgamma2. In conclusion, these results demonstrate that in mouse megakaryocytes, CRP leads to PI 3-kinase-dependent translocation of PLCgamma2 and Btk that are independent of one another, whereas thrombin only induces translocation of Btk through a pathway that is independent of PI 3-kinase activity.
Asunto(s)
Proteínas Portadoras , Isoenzimas/metabolismo , Megacariocitos/enzimología , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Tirosina Quinasas/metabolismo , Fosfolipasas de Tipo C/metabolismo , Agammaglobulinemia Tirosina Quinasa , Agammaglobulinemia/enzimología , Androstadienos/farmacología , Animales , Plaquetas/efectos de los fármacos , Plaquetas/enzimología , Calcio/metabolismo , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas , Inhibidores Enzimáticos/farmacología , Precursores Enzimáticos/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intracelular , Isoenzimas/química , Megacariocitos/efectos de los fármacos , Ratones , Ratones Mutantes , Modelos Biológicos , Fosfatos de Fosfatidilinositol/metabolismo , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosfolipasa C gamma , Transporte de Proteínas , Proteínas/farmacología , Quinasa Syk , Trombina/farmacología , Fosfolipasas de Tipo C/química , Wortmanina , Cromosoma X , Dominios Homologos srcRESUMEN
A 38-kd protein that associates with F-actin structures in activated platelets and endothelial cells was purified, cloned, and characterized. The protein contains an N-terminal PDZ motif, a large intervening sequence, and a C-terminal LIM domain and was identified as the human homolog of rat CLP36. The study showed that CLP36 associates with actin filaments and stress fibers that are formed during shape change and spreading of platelets and during migration and contraction of endothelial cells. CLP36 binds to alpha-actinin-1 as shown by coimmunoprecipitation, pull-down experiments, yeast 2-hybrid analysis, and blot overlay assays and colocalizes with alpha-actinin-1 along endothelial actin stress fibers. In contrast to alpha-actinin-1, CLP36 was absent from focal adhesions in both activated platelets and endothelial cells. The N-terminal part of CLP36 containing the PDZ domain and the intervening region, but not the LIM domain, targeted enhanced green fluorescent protein fusion proteins to stress fibers in endothelial cells. Yeast 2-hybrid analysis demonstrated that the intervening sequence, but not the PDZ or the LIM domain of CLP36, binds to the spectrinlike repeats 2 and 3 of alpha-actinin-1. The study further shows that CLP36 binds to alpha-actinin in resting platelets and translocates as a CLP36/alpha-actinin complex to the newly formed actin cytoskeleton in activated platelets. The results indicate that CLP36 binds via alpha-actinin-1 to actin filaments and stress fibers in activated human platelets and endothelial cells. The study suggests that CLP36 may direct alpha-actinin-1 to specific actin structures and at this position might modulate the function of alpha-actinin-1. (Blood. 2000;96:4236-4245)
Asunto(s)
Citoesqueleto de Actina/metabolismo , Actinas/metabolismo , Plaquetas/metabolismo , Endotelio Vascular/metabolismo , Proteínas de Homeodominio/metabolismo , Activación Plaquetaria , Adenocarcinoma/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células Cultivadas , Clonación Molecular , Citoesqueleto/fisiología , Citoesqueleto/ultraestructura , ADN Complementario/genética , Endotelio Vascular/citología , Genes , Proteínas de Homeodominio/química , Humanos , Proteínas con Dominio LIM , Leucemia Eritroblástica Aguda/patología , Microscopía Fluorescente , Datos de Secuencia Molecular , Proteínas de Neoplasias/química , Proteínas de Neoplasias/genética , Estructura Terciaria de Proteína , Ratas , Proteínas Recombinantes de Fusión/metabolismo , Relación Estructura-Actividad , Células Tumorales Cultivadas , Técnicas del Sistema de Dos Híbridos , Arterias Umbilicales , Venas UmbilicalesRESUMEN
Shape change is an important early event in platelet activation. In this study we show that the Ca2+ chelator BAPTA and the Rho-kinase inhibitor Y-27632 inhibit ADP-induced myosin light chain (MLC) phosphorylation and platelet shape change through distinct pathways and with distinct kinetics. Ca2+ is largely responsible for the initial onset of shape change, whilst Rho-kinase plays a major role in the maintenance of the response. The relative contribution of these two pathways to each stage of the response was dependent on the method of platelet preparation, but in all cases shape change was shown to be downstream of the P2Y1 receptor. Similar observations were made in murine platelets. The shape change response was modulated via changes in cAMP levels, possibly via the P2TAC receptor, but not by tyrosine phosphorylation. We conclude that ADP-induced shape change occurs via the P2Y1 receptor, which can be differentially coupled to Rho-kinase and Ca2+-linked pathways dependent on the method of platelet preparation.
Asunto(s)
Adenosina Difosfato/farmacología , Plaquetas/citología , Ácido Egtácico/análogos & derivados , Proteínas de la Membrana , Amidas/farmacología , Animales , Apirasa/farmacología , Plaquetas/efectos de los fármacos , Plaquetas/fisiología , Calcio/antagonistas & inhibidores , Calcio/farmacología , Señalización del Calcio/efectos de los fármacos , Señalización del Calcio/fisiología , Tamaño de la Célula/efectos de los fármacos , Quelantes/farmacología , Ácido Egtácico/farmacología , Inhibidores Enzimáticos/farmacología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Cinética , Ratones , Activación Plaquetaria/efectos de los fármacos , Activación Plaquetaria/fisiología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/farmacología , Piridinas/farmacología , Receptores Purinérgicos P2/metabolismo , Receptores Purinérgicos P2Y1 , Receptores Purinérgicos P2Y12 , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Quinasas Asociadas a rhoRESUMEN
Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (SIP) are potent bioactive lipids with specific and multiple effects on cells of the vessel wall and blood platelets. In this paper we suggest that these lipid molecules are involved in atherogenesis, pathological vasoconstriction, plaque rupture, and intravascular thrombus formation, which leads us to propose new strategies for the prevention and therapy of cardiovascular diseases. The conclusions are hypothetical, in that the studies were so far mainly carried out on isolated cells or cultured cells in vitro and the results were extrapolated to the situation in vivo.
Asunto(s)
Enfermedades Cardiovasculares/enzimología , Enfermedades Cardiovasculares/etiología , Lisofosfolípidos/metabolismo , Esfingosina/análogos & derivados , Arteriosclerosis/enzimología , Arteriosclerosis/metabolismo , Endotelio Vascular/enzimología , Endotelio Vascular/metabolismo , Humanos , Fosforilación , Transducción de Señal , Esfingosina/metabolismo , Trombosis/enzimología , Trombosis/metabolismoAsunto(s)
Endotelio/efectos de los fármacos , Lipoproteínas LDL/farmacología , Lovastatina/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , Receptores de Superficie Celular/agonistas , Receptores Acoplados a Proteínas G , Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Endotelio/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intracelular , Activación Plaquetaria/efectos de los fármacos , Receptores del Ácido Lisofosfatídico , Transducción de Señal/efectos de los fármacos , Quinasas Asociadas a rhoRESUMEN
In contrast to native low density lipoprotein (LDL), mildly oxidized LDL (mox-LDL) induced platelet shape change and stimulated during shape change the tyrosine phosphorylation of specific proteins including Syk; the translocation of Src, Fyn, and Syk to the cytoskeleton; and the increase of cytosolic Ca(2+) due to mainly Ca(2+) entry. The stimulation of these early signal pathways by mox-LDL was inhibited by desensitization of the lysophosphatidic acid (LPA) receptor and specific LPA receptor antagonists, was independent of the alpha(IIb)beta(3)-integrin, and was mimicked by LPA. Stimulation of tyrosine phosphorylation and Syk activation were independent of the increase of cytosolic Ca(2+) and were suppressed by genistein and two specific inhibitors of the Src family tyrosine kinases, PP1 and PD173956. In contrast to PP1 and PD 173956, genistein prevented shape change by mox-LDL. The results indicate that mox-LDL, through activation of the LPA receptor, stimulates two separate early signal pathways, (a) Src family and Syk tyrosine kinases, and (b) Ca(2+) entry. The activation of these early signaling pathways by mox-LDL probably plays a role in platelet responses subsequent to shape change. The inhibition of mox-LDL-induced platelet activation by LPA receptor antagonists or dietary isoflavonoids such as genistein could have implications in the prevention and therapy of cardiovascular diseases.
Asunto(s)
Plaquetas/metabolismo , Calcio/sangre , Precursores Enzimáticos/metabolismo , Lipoproteínas LDL/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores Acoplados a Proteínas G , Familia-src Quinasas/metabolismo , Tamaño de la Célula , Citoesqueleto/enzimología , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Humanos , Péptidos y Proteínas de Señalización Intracelular , Transporte Iónico , Fosforilación , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Receptores del Ácido Lisofosfatídico , Quinasa Syk , Tirosina/metabolismo , Familia-src Quinasas/antagonistas & inhibidoresRESUMEN
Oxidised low density lipoprotein (LDL) plays an important role in the pathogenesis of atherosclerosis. Here we demonstrate that mildly oxidised (mox) LDL engages the GTPase Rho and its effector molecule p160 Rho-kinase to induce phosphorylation of myosin light chain and of moesin leading to platelet shape change. Pretreatment of platelets with the selective Rho inhibitor C3-transferase from Clostridium botulinum or with the Rho-kinase inhibitor Y-27632 blocked mox-LDL-induced myosin light chain phosphorylation, moesin phosphorylation and shape change. Mox-LDL did not induce an increase in cytosolic Ca(2+) during shape change. We propose that Rho/Rho-kinase inhibition could be a strategy for prevention of the pathologic platelet activation during atherogenesis.
Asunto(s)
Plaquetas/citología , Plaquetas/efectos de los fármacos , Lipoproteínas LDL/farmacología , Proteínas de Microfilamentos/metabolismo , Cadenas Ligeras de Miosina/metabolismo , Amidas/farmacología , Arteriosclerosis/etiología , Plaquetas/metabolismo , Calcio/metabolismo , Tamaño de la Célula/efectos de los fármacos , Tamaño de la Célula/fisiología , Citosol/metabolismo , Inhibidores Enzimáticos/farmacología , Humanos , Técnicas In Vitro , Péptidos y Proteínas de Señalización Intracelular , Fosforilación , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Piridinas/farmacología , Proteínas de Unión al GTP rho/metabolismo , Quinasas Asociadas a rhoRESUMEN
Mildly oxidized low density lipoprotein (mox-LDL) is critically involved in the early atherogenic responses of the endothelium and increases endothelial permeability through an unknown signal pathway. Here we show that (i) exposure of confluent human endothelial cells (HUVEC) to mox-LDL but not to native LDL induces the formation of actin stress fibers and intercellular gaps within minutes, leading to an increase in endothelial permeability; (ii) mox-LDL induces a transient decrease in myosin light chain (MLC) phosphatase that is paralleled by an increase in MLC phosphorylation; (iii) phosphorylated MLC stimulated by mox-LDL is incorporated into stress fibers; (iv) cytoskeletal rearrangements and MLC phosphorylation are inhibited by C3 transferase from Clostridium botulinum, a specific Rho inhibitor, and Y-27632, an inhibitor of Rho kinase; and (v) mox-LDL does not increase intracellular Ca(2+) concentration. Our data indicate that mox-LDL induces endothelial cell contraction through activation of Rho and its effector Rho kinase which inhibits MLC phosphatase and phosphorylates MLC. We suggest that inhibition of this novel cell signaling pathway of mox-LDL could be relevant for the prevention of atherosclerosis.
Asunto(s)
Toxinas Botulínicas , Endotelio Vascular/fisiología , Lipoproteínas LDL/farmacología , Fosfoproteínas Fosfatasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas de Unión al GTP rho/metabolismo , ADP Ribosa Transferasas/farmacología , Amidas/farmacología , Células Cultivadas , Clostridium botulinum , Endotelio Vascular/citología , Endotelio Vascular/efectos de los fármacos , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Homeostasis , Peroxidasa de Rábano Silvestre/farmacocinética , Humanos , Péptidos y Proteínas de Señalización Intracelular , Cinética , Cadenas Ligeras de Miosina/metabolismo , Fosfatasa de Miosina de Cadena Ligera , Fosforilación , Piridinas/farmacología , Venas Umbilicales , Quinasas Asociadas a rhoRESUMEN
Both Rho-kinase and the Ca(2+)/calmodulin-dependent myosin light chain (MLC) kinase increase the phosphorylation of MLC. We show that upon thrombin receptor stimulation by low-dose thrombin or the peptide ligand YFLLRNP, or upon thromboxane receptor activation by U46619, shape change and MLC phosphorylation in human platelets proceed through a pathway that does not involve an increase in cytosolic Ca(2+). Under these conditions, Y-27632, a specific Rho-kinase inhibitor, prevented shape change and reduced the stimulation of MLC-phosphorylation. In contrast, Y-27632 barely affected shape change and MLC-phosphorylation by adenosine diphosphate (ADP), collagen-related peptide, and ionomycin that were associated with an increase in cytosolic Ca(2+) and inhibited by BAPTA-AM/EGTA treatment. Furthermore, C3 exoenzyme, which inactivates Rho, inhibited preferentially the shape change induced by YFLLRNP compared with ADP and ionomycin. The results indicate that the Rho/Rho-kinase pathway is pivotal in mediating the MLC phosphorylation and platelet shape change by low concentrations of certain G protein-coupled platelet receptors, independent of an increase in cytosolic Ca(2+). Our study defines 2 alternate pathways, Rho/Rho-kinase and Ca(2+)/calmodulin-regulated MLC-kinase, that lead independently of each other through stimulation of MLC-phosphorylation to the same physiological response in human platelets (ie, shape change).
Asunto(s)
Plaquetas/metabolismo , Calcio/metabolismo , Proteínas de Unión al GTP/metabolismo , Proteínas de la Membrana/metabolismo , Cadenas Ligeras de Miosina/metabolismo , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacología , Amidas/farmacología , Plaquetas/ultraestructura , Tamaño de la Célula/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Hemostáticos/farmacología , Humanos , Ligandos , Fosforilación , Piridinas/farmacología , Receptores de Trombina/agonistas , Receptores de Trombina/metabolismo , Trombina/farmacología , Vasoconstrictores/farmacología , Proteína de Unión al GTP rhoBRESUMEN
Oxidized low density lipoprotein (LDL) is a key factor in the pathogenesis of atherosclerosis and its thrombotic complications, such as stroke and myocardial infarction. It activates endothelial cells and platelets through mechanisms that are largely unknown. Here, we show that lysophosphatidic acid (LPA) was formed during mild oxidation of LDL and was the active compound in mildly oxidized LDL and minimally modified LDL, initiating platelet activation and stimulating endothelial cell stress-fiber and gap formation. Antagonists of the LPA receptor prevented platelet and endothelial cell activation by mildly oxidized LDL. We also found that LPA accumulated in and was the primary platelet-activating lipid of atherosclerotic plaques. Notably, the amount of LPA within the human carotid atherosclerotic lesion was highest in the lipid-rich core, the region most thrombogenic and most prone to rupture. Given the potent biological activity of LPA on platelets and on cells of the vessel wall, our study identifies LPA as an atherothrombogenic molecule and suggests a possible strategy to prevent and treat atherosclerosis and cardiocerebrovascular diseases.
Asunto(s)
Arteriosclerosis/metabolismo , Arteriosclerosis/fisiopatología , Plaquetas/fisiología , Endotelio Vascular/fisiopatología , Lipoproteínas LDL/metabolismo , Lisofosfolípidos/metabolismo , Activación Plaquetaria , Células Cultivadas , HumanosRESUMEN
Atherosclerotic vascular lesions are considered to be a major cause of ischemic diseases, including myocardial infarction and stroke. Platelet adhesion and aggregation during ischemia-reperfusion are thought to be the initial steps leading to remodeling and reocclusion of the postischemic vasculature. Nitric oxide (NO) inhibits platelet aggregation and smooth muscle proliferation. A major downstream target of NO is cyclic guanosine 3', 5'-monophosphate kinase I (cGKI). To test the intravascular significance of the NO/cGKI signaling pathway in vivo, we have studied platelet-endothelial cell and platelet-platelet interactions during ischemia/reperfusion using cGKI-deficient (cGKI-/-) mice. Platelet cGKI but not endothelial or smooth muscle cGKI is essential to prevent intravascular adhesion and aggregation of platelets after ischemia. The defect in platelet cGKI is not compensated by the cAMP/cAMP kinase pathway supporting the essential role of cGKI in prevention of ischemia-induced platelet adhesion and aggregation.
Asunto(s)
Plaquetas/enzimología , Proteínas Quinasas Dependientes de GMP Cíclico/deficiencia , Agregación Plaquetaria/genética , Animales , Plaquetas/efectos de los fármacos , Adhesión Celular/efectos de los fármacos , Adhesión Celular/genética , Moléculas de Adhesión Celular/metabolismo , Tamaño de la Célula/genética , GMP Cíclico/farmacología , Proteínas Quinasas Dependientes de GMP Cíclico/genética , Endotelio Vascular/enzimología , Técnicas In Vitro , Isquemia/fisiopatología , Ratones , Ratones Noqueados , Microcirculación/fisiopatología , Proteínas de Microfilamentos , Óxido Nítrico/farmacología , Fosfoproteínas/metabolismo , Fosforilación , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Serotonina/metabolismoRESUMEN
It is unknown whether the endocytosis-independent transfer of phospholipids from lipoproteins to platelets is regulated by platelet agonists such as thrombin. The movements of the choline phospholipids phosphatidylcholine and sphingomyelin (labeled with either 14C or the fluorescent pyrenedecanoic acid) between low density lipoproteins and platelets were unaffected by thrombin (0.5 unit/ml). In contrast, thrombin accelerated the import of diacyl phosphatidylethanolamine (PE) and alkenylacyl phosphatidylethanolamine into platelets by about 4-fold. Similarly, thrombin receptor-activating peptide (15 microM), collagen (10 microgram/ml), and ADP (10 microM) enhanced PE uptake. High density lipoprotein particles and egg phosphatidylcholine vesicles were also donors for stimulation of platelet PE import. Part of the [14C]arachidonic acid-labeled PE transferred from low density lipoprotein to platelets activated by thrombin and collagen was metabolized to 14C-eicosanoids. Inhibitors of protein kinase C partially prevented thrombin-induced [14C]PE uptake, while direct activators of protein kinase C increased incorporation of [14C]PE into platelets. Proteinaceous factor(s) recovered in the extracellular medium from ADP- and thrombin-activated platelet suspensions were found to accelerate the transfer of pyrenedecanoic acid-labeled PE between donor and acceptor lipid vesicles. The stimulation of import of ethanolamine phospholipids led to a 2-fold enhancement of the prothrombinase activity of thrombin-activated platelets. Our study demonstrates that physiological platelet stimuli increase specifically the transfer of ethanolamine phospholipids from lipoproteins to platelets through a secretion-dependent mechanism. This might contribute to the increase of procoagulant activity of stimulated platelets.
Asunto(s)
Plaquetas/efectos de los fármacos , Lipoproteínas LDL/metabolismo , Fosfatidiletanolaminas/metabolismo , Adenosina Difosfato/farmacología , Apolipoproteínas B/metabolismo , Ácido Araquidónico/metabolismo , Arginina/análogos & derivados , Transporte Biológico , Coagulación Sanguínea , Colágeno/farmacología , Compuestos de Dansilo/farmacología , Hirudinas/farmacología , Humanos , Fragmentos de Péptidos/farmacología , Fosfolípidos/metabolismo , Activación Plaquetaria , Proteína Quinasa C/antagonistas & inhibidoresRESUMEN
Incubation of human platelets with EGTA under conditions that dissociate the alphaIIbbeta3-integrin stimulated tyrosine phosphorylation of pp72(syk) (6.8-fold) and of proteins of 62 (2. 2-fold), 68 (2.5-fold) and 130 kDa (1.4-fold). Stimulation of tyrosine phosphorylation of pp72(syk) was associated with an increase of pp72(syk) kinase activity. In contrast to pp72(syk), tyrosine phosphorylation of the focal adhesion kinase pp125(FAK) was not stimulated by EGTA. Preincubation of platelets with the monoclonal antibody P2, which binds to the alphaIIbbeta3 complex and thus stabilizes it, strongly reduced the increase of tyrosine phosphorylation of pp72(syk), p62, and p68 induced by EGTA. The Y2/51 monoclonal antibody, which recognizes only the beta3 glycoprotein, did not inhibit the stimulation of protein tyrosine phosphorylation evoked by EGTA. Stimulation of tyrosine phosphorylation of pp72(syk), p62, p68, and p130 induced by EGTA was not observed in thrombasthenic platelets, which lack the alphaIIbbeta3-integrin. The results indicate that the dissociation of the alphaIIbbeta3 complex in intact platelets activates pp72(syk). The mechanism of activation was found to be insensitive to inhibition by cAMP and cGMP and only partially dependent on cytosolic Ca2+, suggesting a close functional coupling of alphaIIbbeta3-integrin and pp72(syk). Since platelets retain their discoid shape after EGTA treatment, we further conclude that pp72(syk) stimulation alone is not sufficient for platelet activation.